Cargando…
Clinical features and treatment outcomes of opportunistic infections among human T-lymphotrophic virus type 1 (HTLV-1) carriers and patients with adult T-cell leukemia-lymphoma (ATL) at a single institution from 2006 to 2016
As opportunistic infections among human T-lymphotrophic virus type 1 (HTLV-1) carriers and patients with adult T-cell leukemia/lymphoma (ATL) pose a serious problem, it is necessary to clarify their clinical characteristics and outcomes in these patients. We retrospectively analyzed the clinical fea...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JSLRT
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954174/ https://www.ncbi.nlm.nih.gov/pubmed/31866618 http://dx.doi.org/10.3960/jslrt.18032 |
_version_ | 1783486754233253888 |
---|---|
author | Kawano, Noriaki Nagahiro, Yuri Yoshida, Shuro Tahara, Yoshihiro Himeji, Daisuke Kuriyama, Takuro Tochigi, Taro Nakaike, Takashi Shimokawa, Tomonori Yamashita, Kiyoshi Ochiai, Hidenobu Marutsuka, Kouske Mashiba, Koichi Shimoda, Kazuya Teshima, Takanori Kikuchi, Ikuo |
author_facet | Kawano, Noriaki Nagahiro, Yuri Yoshida, Shuro Tahara, Yoshihiro Himeji, Daisuke Kuriyama, Takuro Tochigi, Taro Nakaike, Takashi Shimokawa, Tomonori Yamashita, Kiyoshi Ochiai, Hidenobu Marutsuka, Kouske Mashiba, Koichi Shimoda, Kazuya Teshima, Takanori Kikuchi, Ikuo |
author_sort | Kawano, Noriaki |
collection | PubMed |
description | As opportunistic infections among human T-lymphotrophic virus type 1 (HTLV-1) carriers and patients with adult T-cell leukemia/lymphoma (ATL) pose a serious problem, it is necessary to clarify their clinical characteristics and outcomes in these patients. We retrospectively analyzed the clinical features and outcomes of opportunistic infections in 127 HTLV-1 carriers and 153 ATL patients between 2006 and 2016. The cumulative incidence rates of opportunistic infections among HTLV-1 carriers and ATL patients were 1.5% (2/127) and 6.5% (10/153), respectively. The etiology of opportunistic infections was as follows: fungal infections (3 cases), pneumocystis pneumonia, and cytomegalovirus (CMV) infections. Even after aggressive treatment, the prognosis of opportunistic infections was poor (50% of overall survival at 28 days). Regarding prognostic factors affecting the OS of opportunistic infections, higher SOFA scores (especially the respiratory subscore) and higher LDH values were identified by univariate analysis. Moreover, 3 out of 6 patients achieved spontaneous remission of ATL as the short-term outcome after the development of opportunistic infection. However, 5 out of 6 surviving patients exhibited ATL progression or relapse after a median of 194 days (133–226) after contracting an opportunistic infection as the long-term outcome of ATL. In conclusion, opportunistic infections should be carefully followed among HTLV-1 carriers and ATL patients because of their aggressive clinical course and poor outcomes. Furthermore, early diagnosis and subsequent prompt treatment are necessary in clinical practice. |
format | Online Article Text |
id | pubmed-6954174 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | JSLRT |
record_format | MEDLINE/PubMed |
spelling | pubmed-69541742020-01-13 Clinical features and treatment outcomes of opportunistic infections among human T-lymphotrophic virus type 1 (HTLV-1) carriers and patients with adult T-cell leukemia-lymphoma (ATL) at a single institution from 2006 to 2016 Kawano, Noriaki Nagahiro, Yuri Yoshida, Shuro Tahara, Yoshihiro Himeji, Daisuke Kuriyama, Takuro Tochigi, Taro Nakaike, Takashi Shimokawa, Tomonori Yamashita, Kiyoshi Ochiai, Hidenobu Marutsuka, Kouske Mashiba, Koichi Shimoda, Kazuya Teshima, Takanori Kikuchi, Ikuo J Clin Exp Hematop Original Article As opportunistic infections among human T-lymphotrophic virus type 1 (HTLV-1) carriers and patients with adult T-cell leukemia/lymphoma (ATL) pose a serious problem, it is necessary to clarify their clinical characteristics and outcomes in these patients. We retrospectively analyzed the clinical features and outcomes of opportunistic infections in 127 HTLV-1 carriers and 153 ATL patients between 2006 and 2016. The cumulative incidence rates of opportunistic infections among HTLV-1 carriers and ATL patients were 1.5% (2/127) and 6.5% (10/153), respectively. The etiology of opportunistic infections was as follows: fungal infections (3 cases), pneumocystis pneumonia, and cytomegalovirus (CMV) infections. Even after aggressive treatment, the prognosis of opportunistic infections was poor (50% of overall survival at 28 days). Regarding prognostic factors affecting the OS of opportunistic infections, higher SOFA scores (especially the respiratory subscore) and higher LDH values were identified by univariate analysis. Moreover, 3 out of 6 patients achieved spontaneous remission of ATL as the short-term outcome after the development of opportunistic infection. However, 5 out of 6 surviving patients exhibited ATL progression or relapse after a median of 194 days (133–226) after contracting an opportunistic infection as the long-term outcome of ATL. In conclusion, opportunistic infections should be carefully followed among HTLV-1 carriers and ATL patients because of their aggressive clinical course and poor outcomes. Furthermore, early diagnosis and subsequent prompt treatment are necessary in clinical practice. JSLRT 2019-12-22 /pmc/articles/PMC6954174/ /pubmed/31866618 http://dx.doi.org/10.3960/jslrt.18032 Text en © 2019 by The Japanese Society for Lymphoreticular Tissue Research https://creativecommons.org/licenses/by-nc-sa/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution ShareAlike (CC BY-NC-SA) 4.0 License. |
spellingShingle | Original Article Kawano, Noriaki Nagahiro, Yuri Yoshida, Shuro Tahara, Yoshihiro Himeji, Daisuke Kuriyama, Takuro Tochigi, Taro Nakaike, Takashi Shimokawa, Tomonori Yamashita, Kiyoshi Ochiai, Hidenobu Marutsuka, Kouske Mashiba, Koichi Shimoda, Kazuya Teshima, Takanori Kikuchi, Ikuo Clinical features and treatment outcomes of opportunistic infections among human T-lymphotrophic virus type 1 (HTLV-1) carriers and patients with adult T-cell leukemia-lymphoma (ATL) at a single institution from 2006 to 2016 |
title | Clinical features and treatment outcomes of opportunistic infections among human T-lymphotrophic virus type 1 (HTLV-1) carriers and patients with adult T-cell leukemia-lymphoma (ATL) at a single institution from 2006 to 2016 |
title_full | Clinical features and treatment outcomes of opportunistic infections among human T-lymphotrophic virus type 1 (HTLV-1) carriers and patients with adult T-cell leukemia-lymphoma (ATL) at a single institution from 2006 to 2016 |
title_fullStr | Clinical features and treatment outcomes of opportunistic infections among human T-lymphotrophic virus type 1 (HTLV-1) carriers and patients with adult T-cell leukemia-lymphoma (ATL) at a single institution from 2006 to 2016 |
title_full_unstemmed | Clinical features and treatment outcomes of opportunistic infections among human T-lymphotrophic virus type 1 (HTLV-1) carriers and patients with adult T-cell leukemia-lymphoma (ATL) at a single institution from 2006 to 2016 |
title_short | Clinical features and treatment outcomes of opportunistic infections among human T-lymphotrophic virus type 1 (HTLV-1) carriers and patients with adult T-cell leukemia-lymphoma (ATL) at a single institution from 2006 to 2016 |
title_sort | clinical features and treatment outcomes of opportunistic infections among human t-lymphotrophic virus type 1 (htlv-1) carriers and patients with adult t-cell leukemia-lymphoma (atl) at a single institution from 2006 to 2016 |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954174/ https://www.ncbi.nlm.nih.gov/pubmed/31866618 http://dx.doi.org/10.3960/jslrt.18032 |
work_keys_str_mv | AT kawanonoriaki clinicalfeaturesandtreatmentoutcomesofopportunisticinfectionsamonghumantlymphotrophicvirustype1htlv1carriersandpatientswithadulttcellleukemialymphomaatlatasingleinstitutionfrom2006to2016 AT nagahiroyuri clinicalfeaturesandtreatmentoutcomesofopportunisticinfectionsamonghumantlymphotrophicvirustype1htlv1carriersandpatientswithadulttcellleukemialymphomaatlatasingleinstitutionfrom2006to2016 AT yoshidashuro clinicalfeaturesandtreatmentoutcomesofopportunisticinfectionsamonghumantlymphotrophicvirustype1htlv1carriersandpatientswithadulttcellleukemialymphomaatlatasingleinstitutionfrom2006to2016 AT taharayoshihiro clinicalfeaturesandtreatmentoutcomesofopportunisticinfectionsamonghumantlymphotrophicvirustype1htlv1carriersandpatientswithadulttcellleukemialymphomaatlatasingleinstitutionfrom2006to2016 AT himejidaisuke clinicalfeaturesandtreatmentoutcomesofopportunisticinfectionsamonghumantlymphotrophicvirustype1htlv1carriersandpatientswithadulttcellleukemialymphomaatlatasingleinstitutionfrom2006to2016 AT kuriyamatakuro clinicalfeaturesandtreatmentoutcomesofopportunisticinfectionsamonghumantlymphotrophicvirustype1htlv1carriersandpatientswithadulttcellleukemialymphomaatlatasingleinstitutionfrom2006to2016 AT tochigitaro clinicalfeaturesandtreatmentoutcomesofopportunisticinfectionsamonghumantlymphotrophicvirustype1htlv1carriersandpatientswithadulttcellleukemialymphomaatlatasingleinstitutionfrom2006to2016 AT nakaiketakashi clinicalfeaturesandtreatmentoutcomesofopportunisticinfectionsamonghumantlymphotrophicvirustype1htlv1carriersandpatientswithadulttcellleukemialymphomaatlatasingleinstitutionfrom2006to2016 AT shimokawatomonori clinicalfeaturesandtreatmentoutcomesofopportunisticinfectionsamonghumantlymphotrophicvirustype1htlv1carriersandpatientswithadulttcellleukemialymphomaatlatasingleinstitutionfrom2006to2016 AT yamashitakiyoshi clinicalfeaturesandtreatmentoutcomesofopportunisticinfectionsamonghumantlymphotrophicvirustype1htlv1carriersandpatientswithadulttcellleukemialymphomaatlatasingleinstitutionfrom2006to2016 AT ochiaihidenobu clinicalfeaturesandtreatmentoutcomesofopportunisticinfectionsamonghumantlymphotrophicvirustype1htlv1carriersandpatientswithadulttcellleukemialymphomaatlatasingleinstitutionfrom2006to2016 AT marutsukakouske clinicalfeaturesandtreatmentoutcomesofopportunisticinfectionsamonghumantlymphotrophicvirustype1htlv1carriersandpatientswithadulttcellleukemialymphomaatlatasingleinstitutionfrom2006to2016 AT mashibakoichi clinicalfeaturesandtreatmentoutcomesofopportunisticinfectionsamonghumantlymphotrophicvirustype1htlv1carriersandpatientswithadulttcellleukemialymphomaatlatasingleinstitutionfrom2006to2016 AT shimodakazuya clinicalfeaturesandtreatmentoutcomesofopportunisticinfectionsamonghumantlymphotrophicvirustype1htlv1carriersandpatientswithadulttcellleukemialymphomaatlatasingleinstitutionfrom2006to2016 AT teshimatakanori clinicalfeaturesandtreatmentoutcomesofopportunisticinfectionsamonghumantlymphotrophicvirustype1htlv1carriersandpatientswithadulttcellleukemialymphomaatlatasingleinstitutionfrom2006to2016 AT kikuchiikuo clinicalfeaturesandtreatmentoutcomesofopportunisticinfectionsamonghumantlymphotrophicvirustype1htlv1carriersandpatientswithadulttcellleukemialymphomaatlatasingleinstitutionfrom2006to2016 |